With decades of combined business experience in the life science sectors, Norcliffe Capital provides more than capital to support our investments. We use our experience and expertise to select UK based growth companies in our specialist sectors and support them throughout their commercial journey.
Norcliffe Capital’s investors have the opportunity to invest directly in individual private companies in the life science sectors of MedTech and biotechnology.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
If you are interested in learning more about how to protect yourself, visit the FCA’s website here.